Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 3
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) i…
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Verified
$1,200
Gilead SciencesNCT06801834
Phase 1
Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received pl…
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Estimated
~$10 – $6,250
Yale UniversityNCT07113691
Phase 2
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tum…
Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Estimated
~$10 – $7,500
Bindu R PotugariNCT07339059